Zacks Investment Research on MSN
OCGN gene-agnostic eye therapy could shift retinal drug development
Ocugen OCGN is building its ocular portfolio around a modifier gene therapy idea: instead of designing a therapy for a single ...
Explore the latest developments showcased at World ADC, highlighting smarter payloads and precise targeting in drug discovery ...
Early 2026 has brought a series of consequential regulatory moves from the FDA, each reflecting a common thread: the agency ...
The Mystra platform, developed over 10 years, offers biopharma partners proven analytical power to turn months of R&D into minutes, dramatically increasing the availability of quality genetic insights ...
4don MSN
How a tryptophan-rich allosteric communication network helps activate a major drug target receptor
A multinational research team led by researchers at Institute of Science Tokyo, RIKEN, and the University of Toronto has ...
Find out how self-driving labs utilise data-driven approaches to enhance drug discovery efficiency and innovation.
Cells face constant threats from inside and out. Thus, they’ve evolved sophisticated stress response pathways such as the unfolded protein response (UPR), ...
London biotech startup Ternary Therapeutics has raised £3.6m to scale its AI-powered platform designed to engineer molecular ...
Smart multi-target drugs are reshaping modern therapeutics by addressing the complex, interconnected pathways that drive diseases like Alzheimer’s, cancer, and major depressive disorder. Advances in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results